Nonkulie Dladla, MD
Internal Medicine · Montclair, NJNPI 1083836894
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 95 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 34.8% of the total. 2025 is the largest year on record at $900, 2.1 times the $426 reported in 2023.
Across 95 payments — averaging $23.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$774
- Exact Sciences$130
- GSK$116
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$108
- Astellas Pharma US Inc$104
- Novo Nordisk$83
- plus $908 from 21 others
What the payments were for
- Food & beverage$2,223100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 33 | $774 |
| Exact Sciences | 5 | $130 |
| GSK | 5 | $116 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $108 |
| Astellas Pharma US Inc | 4 | $104 |
| Novo Nordisk | 4 | $83 |
| Ardelyx, Inc. | 3 | $82 |
| AstraZeneca | 4 | $80 |
| Lundbeck LLC | 4 | $80 |
| Gilead | 3 | $71 |
| Pfizer | 3 | $62 |
| Sanofi | 2 | $61 |
| Almatica Pharma LLC | 2 | $58 |
| Intra-sana Laboratories | 2 | $52 |
| Upsher-smith Laboratories LLC | 2 | $50 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Phadia US Inc. | 2 | $42 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $40 |
| Merck | 1 | $31 |
| Ironwood Pharmaceuticals, Inc | 1 | $25 |
| Bayer | 1 | $23 |
| Genentech USA, Inc. | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Amgen | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$2,223 in reported general payments places this provider in the 75th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $683 |
| Amlodipine Besylate | 32 | $194 |
| Tamsulosin Hcl | 13 | $184 |
| Levothyroxine Sodium | 21 | $162 |
| Losartan Potassium | 13 | $111 |
| Rosuvastatin Calcium | 13 | $108 |
| Alprazolam | 11 | $86 |
| Zolpidem Tartrate | 11 | $63 |
| Hydrochlorothiazide | 14 | $12 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Montclair
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
- Angel LazoSecaucus$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.